Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 289

The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.

Inhaled budesonide for COVID-19 in people at high risk of complications in the community in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial

Open access
Yu, Ly-Mee, Bafadhel, Mona, Dorward, Jienchi, Hayward, Gail, Saville, Benjamin R, Gbinigie, Oghenekome, Van Hecke, Oliver, Ogburn, Emma, Evans, Philip H, Thomas, Nicholas P B, Patel, Mahendra G, Richards, Duncan, Berry, Nicholas, Detry, Michelle A, Saunders, Christina, Fitzgerald, Mark, Harris, Victoria, Shanyinde, Milensu, de Lusignan, Simon, Andersson, Monique I, Barnes, Peter J, Russell, Richard E K, Nicolau, Dan V, Ramakrishnan, Sanjay, Hobbs, F D Richard, Butler, Christopher C, Yu, Ly-Mee, Bafadhel, Mona, Dorward, Jienchi, Hayward, Gail, Saville, Benjamin R, Gbinigie, Oghenekome, van Hecke, Oliver, Ogburn, Emma, Evans, Philip H, Thomas, Nicholas PB, Patel, Mahendra G, Richards, Duncan, Berry, Nicholas, Detry, Michelle A, Saunders, Christina T, Fitzgerald, Mark, Harris, Victoria, Shanyinde, Milensu, de Lusignan, Simon, Andersson, Monique I, Barnes, Peter J, Russell, Richard EK, Nicolau, Dan V, Ramakrishnan, Sanjay, Hobbs, FD Richard, Butler, Christopher C · 2021 · The Lancet

Abstract

BACKGROUND: A previous efficacy trial found benefit from inhaled budesonide for COVID-19 in patients not admitted to hospital, but effectiveness in high-risk individuals is unknown. We aimed to establish whether inhaled budesonide reduces time to recovery and COVID-19-related hospital admissions or deaths among people at high risk of complications in the community. METHODS: PRINCIPLE is a multicentre, open-label, multi-arm, randomised, controlled, adaptive platform trial done remotely from a central trial site and at primary care centres in the UK. Eligible participants were aged 65 years or older or 50 years or older with comorbidities, and unwell for up to 14 days with suspected COVID-19 but not admitted to hospital. Participants were randomly assigned to usual care, usual care plus inhaled budesonide (800 μg twice daily for 14 days), or usual care plus other interventions, and followed up for 28 days. Participants were aware of group assignment. The coprimary endpoints are time to first self-reported recovery and hospital admission or death related to COVID-19, within 28 days, analysed using Bayesian models. The primary analysis population included all eligible SARS-CoV-2-positive participants randomly assigned to budesonide, usual care, and other interventions, from the start of the platform trial until the budesonide group was closed. This trial is registered at the ISRCTN registry (ISRCTN86534580) and is ongoing. FINDINGS: The trial began enrolment on April 2, 2020, with randomisation to budesonide from Nov 27, 2020, until March 31, 2021, when the prespecified time to recovery superiority criterion was met. 4700 participants were randomly assigned to budesonide (n=1073), usual care alone (n=1988), or other treatments (n=1639). The primary analysis model includes 2530 SARS-CoV-2-positive participants, with 787 in the budesonide group, 1069 in the usual care group, and 974 receiving other treatments. There was a benefit in time to first self-reported recovery of an estimated 2·94 days (95% Bayesian credible interval [BCI] 1·19 to 5·12) in the budesonide group versus the usual care group (11·8 days [95% BCI 10·0 to 14·1] vs 14·7 days [12·3 to 18·0]; hazard ratio 1·21 [95% BCI 1·08 to 1·36]), with a probability of superiority greater than 0·999, meeting the prespecified superiority threshold of 0·99. For the hospital admission or death outcome, the estimated rate was 6·8% (95% BCI 4·1 to 10·2) in the budesonide group versus 8·8% (5·5 to 12·7) in the usual care group (estimated absolute difference 2·0% [95% BCI -0·2 to 4·5]; odds ratio 0·75 [95% BCI 0·55 to 1·03]), with a probability of superiority 0·963, below the prespecified superiority threshold of 0·975. Two participants in the budesonide group and four in the usual care group had serious adverse events (hospital admissions unrelated to COVID-19). INTERPRETATION: Inhaled budesonide improves time to recovery, with a chance of also reducing hospital admissions or deaths (although our results did not meet the superiority threshold), in people with COVID-19 in the community who are at higher risk of complications. FUNDING: National Institute of Health Research and United Kingdom Research Innovation.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s0140-6736(21)01744-x

Cites

23 of 23 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 23 references

Cited by

See all 289

Metadata

Authors
Yu, L.-M., Bafadhel, M., Dorward, J., Hayward, G., Saville, B. R., Gbinigie, O., Van Hecke, O., Ogburn, E., Evans, P. H., Thomas, N. P. B., Patel, M. G., Richards, D., Berry, N., Detry, M. A., Saunders, C., Fitzgerald, M., Harris, V., Shanyinde, M., de Lusignan, S., Andersson, M. I., Barnes, P. J., Russell, R. E. K., Nicolau, D. V., Ramakrishnan, S., Hobbs, F. D. R., Butler, C. C., Yu, L.-M., Bafadhel, M., Dorward, J., Hayward, G., Saville, B. R., Gbinigie, O., van Hecke, O., Ogburn, E., Evans, P. H., Thomas, N. P., Patel, M. G., Richards, D., Berry, N., Detry, M. A., Saunders, C. T., Fitzgerald, M., Harris, V., Shanyinde, M., de Lusignan, S., Andersson, M. I., Barnes, P. J., Russell, R. E., Nicolau, D. V., Ramakrishnan, S., Hobbs, F. R., & Butler, C. C.
Venue
The Lancet
Publisher
Elsevier BV
Published
2021-09
Volume
398
Issue
10303
Pages
843-855
ISSN
  • 0099-5355 (ISSN-L)
  • 0140-6736
OpenAlex
W3188676168
Cited by
289
References
23
FWCI
18.88
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Inhaled budesonide for COVID-19 in people at high risk of complications in the community in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial. https://app.cochat.ai/papers/10.1016/s0140-6736(21)01744-x
The paper
Yu, L.-M., Bafadhel, M., Dorward, J., Hayward, G., Saville, B. R., Gbinigie, O., Van Hecke, O., Ogburn, E., Evans, P. H., Thomas, N. P. B., Patel, M. G., Richards, D., Berry, N., Detry, M. A., Saunders, C., Fitzgerald, M., Harris, V., Shanyinde, M., de Lusignan, S., . . . Butler, C. C. (2021). Inhaled budesonide for COVID-19 in people at high risk of complications in the community in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial. The Lancet. https://doi.org/10.1016/s0140-6736(21)01744-x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.